Marrone Bio Innovations I... (MBII)
Marrone Bio Innovations Statistics
Share Statistics
Marrone Bio Innovations has 0 shares outstanding. The number of shares has increased by 4.03% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 4.03% |
| Shares Change (QoQ) | 0.93% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 88.51M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -7.61 and the forward PE ratio is null. Marrone Bio Innovations's PEG ratio is 0.
| PE Ratio | -7.61 |
| Forward PE | n/a |
| PS Ratio | 2.84 |
| Forward PS | n/a |
| PB Ratio | 4.25 |
| P/FCF Ratio | -11.39 |
| PEG Ratio | 0 |
Enterprise Valuation
Marrone Bio Innovations has an Enterprise Value (EV) of 143.78M.
| EV / Sales | 3.24 |
| EV / EBITDA | -13.86 |
| EV / EBIT | -14.43 |
| EV / FCF | -13.01 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 1.26.
| Current Ratio | 0.94 |
| Quick Ratio | 0.75 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | -3.61 |
| Debt / FCF | -3.39 |
| Interest Coverage | -9.52 |
Financial Efficiency
Return on Equity is -55.83% and Return on Invested Capital is -22.31%.
| Return on Equity | -55.83% |
| Return on Assets | -19.02% |
| Return on Invested Capital | -22.31% |
| Revenue Per Employee | $289.61K |
| Profits Per Employee | $-108.2K |
| Employee Count | 153 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | 45K |
| Effective Tax Rate | -0.27% |
Stock Price Statistics
The stock price has increased by 0.24% in the last 52 weeks. The beta is 0.36, so Marrone Bio Innovations's price volatility has been higher than the market average.
| Beta | 0.36 |
| 52-Week Price Change | 0.24% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 32.81 |
| Average Volume (20 Days) | 873.21K |
Income Statement
In the last 12 months, Marrone Bio Innovations had revenue of 44.31M and earned -16.55M in profits. Earnings per share was -0.09.
| Revenue | 44.31M |
| Gross Profit | 27.25M |
| Operating Income | -14.94M |
| Net Income | -16.55M |
| EBITDA | -10.37M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 19.62M in cash and 37.49M in debt, giving a net cash position of -17.87M.
| Cash & Cash Equivalents | 19.62M |
| Total Debt | 37.49M |
| Net Cash | -17.87M |
| Retained Earnings | -357.37M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -9.96M and capital expenditures -1.09M, giving a free cash flow of -11.05M.
| Operating Cash Flow | -9.96M |
| Capital Expenditures | -1.09M |
| Free Cash Flow | -11.05M |
| FCF Per Share | -0.06 |
Margins
Gross margin is 61.49%, with operating and profit margins of -33.71% and -37.36%.
| Gross Margin | 61.49% |
| Operating Margin | -33.71% |
| Pretax Margin | -37.26% |
| Profit Margin | -37.36% |
| EBITDA Margin | -23.41% |
| EBIT Margin | -33.71% |
| FCF Margin | -24.95% |
Dividends & Yields
MBII does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.15% |
| FCF Yield | -8.78% |
Analyst Forecast
Currently there are no analyst rating for MBII.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |